Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: Successful rescue therapy with tenofovir

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 8, 2008, Pages 773-777

  Leemans, Wilhelmus F ^a   Niesters, Hubert G ^a   Van Der Eijk, Annemiek A ^a   Janssen, Harry L ^a   Schalm, Solko W ^a   De Man, Robert A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Entecavir; Hepatitis B virus; Lamivudine; Resistance; Tenofovir; Tyrosinemethionineaspartateaspartate

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADD ON THERAPY; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; CROSS RESISTANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; BLOOD; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MULTIDRUG RESISTANCE; VIROLOGY;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; PHOSPHONIC ACIDS; VIRAL LOAD;

EID: 52749088340     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f793d6     Document Type: Article

References (43)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107.
2. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
3. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68.
4. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
5. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172-180.
6. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis J Hepatol 2006; 44:283-290.
7. Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie M, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42 (Suppl 2):17.
8. Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999; 43:190-193.
9. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039-2049.
10. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
11. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129:1198-1209.
12. Colonno R, Rose R, Levine S, Baldick J, Pokornowski K, Plym M, et al. Entecavir two year resistance update: no resistance observed in nucleotide naïve patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology 2005; 42 (Suppl 1):573A.
13. Colonno RJ, Rose RE, Levine SM, Pokornowski K, Plym M, Yu CF, et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients. Hepatology 2004; 40:1140A.
14. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WEt. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10:625-633.
15. de Vries-Sluijs TE, van der Eijk AA, Hansen BE, Osterhaus AD, de Man RA, van der Ende ME. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients. J Clin Virol 2006; 36:60-63.
16. van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40:1421-1425.
17. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group. J Clin Microbiol 1999; 37:68-73.
18. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000; 38:2897-2901.
19. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751-757.
20. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34 (4 Pt 1):785-791.
21. Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46:2525-2532.
22. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107:449-455.
23. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemothe 2004; 48:3498-3507.
24. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46:531-538.
25. Doo E, Liang TJ. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001; 120:1000-1008.
26. Zhou T, Saputelli J, Aldrich CE, Deslauriers M, Condreay LD, Mason WS. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 999; 43:1947-1954.
27. Ryu SH, Chung Y-H, Kim JA, Choi MH, Lee Y-S, Jung SW, et al. Viral resistance to adefovir therapy results from reappeared wild type hepatitis B virus in majority of patiens with YMDD mutants. J Hepatol 2006; 44 (Suppl 2):S190.
28. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41:1391-1398.
29. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75:4771-4779.
30. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to ( - )-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45: 2495-2501.
31. Fu L, Liu SH, Cheng YC. Sensitivity of L-( - )2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999; 57:1351-1359.
32. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36:710-722.
33. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004;9:353-363.
34. Ono-Nita SK, Kato N, Shiratori Y, Carrilho FJ, Omata M. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob Agents Chemother 2002; 46: 2602-2605.
35. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7:161-165.
36. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42:1414-1419.
37. van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005; 12:364-372.
38. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43:1385-1391.
39. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B. J Med Virol 1999; 59:270-276.
40. Lee Y, Chung Y, Ryu SH, Kim JA, Choi MH, Jung SW, et al. Hepatitis B virus with rtL80V/I mutation associates with poor response to adefovir dipivoxil therapy. Hepatology 2005; 42 (Suppl 1):575A.
41. Lee CH, Yeon JE, Pyo S, Kim JH, Chung HJ, Gyeonggido Y, et al. More frequent and earlier emergence of adefovir (ADV) resistance mutations in lamivudine resistant patients treated with ADV compared to previously reported nucleoside-treatment naïve patients. Hepatology 2005; 42 (Suppl 1):593A.
42. Locarnini SA, Ayres A, Thompson G, Sozzi V, Angus P, Sivert W, et al. Molecular moddeling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutation. Hepatology 2004; 40 (Suppl 1):246A.
43. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-734.